切换至 "中华医学电子期刊资源库"

中华肺部疾病杂志(电子版) ›› 2025, Vol. 18 ›› Issue (06) : 1027 -1030. doi: 10.3877/cma.j.issn.1674-6902.2025.06.031

综述

淋巴结转移与非转移对原发性支气管肺癌免疫微环境及免疫治疗的影响
俞颖倩1, 徐兴祥2,()   
  1. 1215600 苏州,张家港第五人民医院
    2215000 苏州,苏州明基医院
  • 收稿日期:2025-02-15 出版日期:2025-12-25
  • 通信作者: 徐兴祥

Impact of lymph node metastasis and non-metastasis on the immune microenvironment and immunotherapy in primary bronchogenic carcinoma

Yingqian Yu, Xingxiang Xu()   

  • Received:2025-02-15 Published:2025-12-25
  • Corresponding author: Xingxiang Xu
引用本文:

俞颖倩, 徐兴祥. 淋巴结转移与非转移对原发性支气管肺癌免疫微环境及免疫治疗的影响[J/OL]. 中华肺部疾病杂志(电子版), 2025, 18(06): 1027-1030.

Yingqian Yu, Xingxiang Xu. Impact of lymph node metastasis and non-metastasis on the immune microenvironment and immunotherapy in primary bronchogenic carcinoma[J/OL]. Chinese Journal of Lung Diseases(Electronic Edition), 2025, 18(06): 1027-1030.

肺癌是全球癌症相关死亡的主要原因,淋巴结转移是影响患者预后的关键因素。淋巴结作为免疫系统的关键组成部分,有过滤、监测和调节免疫应答的作用。当淋巴结转移时,免疫微环境往往会发生重大变化,影响免疫系统的功能及对免疫治疗的应答。新辅助免疫治疗可在部分淋巴结转移患者中诱导显著的病理降期并改善生存,但高免疫抑制微环境也可能导致治疗抵抗。分析淋巴结转移与非转移状态下免疫微环境的差异,以及这些差异对免疫治疗的影响,为肺癌患者的免疫治疗提供参考。

1
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
2
陈旭,牛凯,孙建国. 放疗联合免疫治疗对驱动基因阴性NSCLC的困惑分析及应对策略[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(3): 341-348.
3
Zheng J, Jia L, Mori S, et al. Evaluation of metastatic niches in distant organs after surgical removal of tumor-bearing lymph nodes[J]. BMC cancer, 2018, 18(1): 608.
4
Erler JT, Bennewith KL, Cox TR, et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche[J]. Cancer cell, 2009, 15(1): 35-44.
5
Perryman L, Erler JT. Lysyl oxidase in cancer research[J]. Future Oncol, 2014, 10(9): 1709-1717.
6
Li YL, Hung WC. Reprogramming of sentinel lymph node microenvironment during tumor metastasis[J]. J Biomed Sci, 2022, 29(1): 84.
7
Domogalla MP, Rostan PV, Raker VK, et al. Tolerance through education: how tolerogenic dendritic cells shape immunity[J]. Front Immunol, 2017, 8: 1764.
8
Devito NC, Plebanek MP, Theivanthiran B, et al. Role of tumor-mediated dendritic cell tolerization in immune evasion [J]. Front Immunol, 2019, 10: 2876.
9
Van Pul KM, Vuylsteke R, Van De Ven R, et al. Selectively hampered activation of lymph node-resident dendritic cells precedes profound T cell suppression and metastatic spread in the breast cancer sentinel lymph node[J]. J Immunother Cancer, 2019, 7(1): 133.
10
Aspord C, Leccia M T, Charles J, et al. Plasmacytoid dendritic cells support melanoma progression by promoting Th2 and regulatory immunity through OX40L and ICOSL [J]. Cancer immunol Res, 2013, 1(6): 402-415.
11
Baban B, Chandler PR, Sharma MD, et al. IDO activates regulatory T cells and blocks their conversion into Th17-like T cells [J]. J Immunol, 2009, 183(4): 2475-2483.
12
Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis[J]. Cell, 2010, 141(1): 39-51.
13
Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles[J]. Nat Methods, 2015, 12(5): 453-457.
14
Dong B, Wu C, Huang L, et al. Macrophage-related SPP1 as a potential biomarker for early lymph node metastasis in lung adenocarcinoma[J]. Front Cell Dev Biol, 2021, 9: 739358.
15
Wu K, Lin K, Li X, et al. Redefining tumor-associated macrophage subpopulations and functions in the tumor microenvironment[J]. Front Immunol, 2020, 11: 1731.
16
Wang Y, Wang J, Yang C, et al. A study of the correlation between M2 macrophages and lymph node metastasis of colorectal carcinoma[J]. World J Surg Oncol 2021, 19(1): 91.
17
Kong W, Wei M, Liu R, et al. Prognostic value of CD169-positive macrophages in various tumors: a meta-analysis[J]. Bioengineered, 2021, 12(1): 8505-8514.
18
Peng JM, Su YL. Lymph node metastasis and tumor-educated immune tolerance: Potential therapeutic targets against distant metastasis[J]. Biochem Pharmacol, 2023, 215: 115731.
19
Masucci MT, Minopoli M, Carriero MV. Tumor associated neutrophils. their role in tumorigenesis, metastasis, prognosis and therapy[J]. Front Oncol, 2019, 9: 1146.
20
Hiramatsu S, Tanaka H, Nishimura J, et al. Neutrophils in primary gastric tumors are correlated with neutrophil infiltration in tumor-draining lymph nodes and the systemic inflammatory response[J]. BMC Immunology, 2018, 19(1): 13.
21
Raniszewska A, Vroman H, Dumoulin D, et al. PD-L1(+) lung cancer stem cells modify the metastatic lymph-node immunomicroenvironment in nsclc patients[J]. Cancer Immunology Immunotherapy, 2021, 70(2): 453-461.
22
Kwiecien I, Rutkowska E, Sokołowski R, et al. Effector memory T cells and CD45RO+ regulatory T cells in metastatic vs. non-metastatic lymph nodes in lung cancer patients[J]. Front Immunol, 2022, 13: 864497.
23
Rahim MK, Okholm TLH, Jones KB, et al. Dynamic CD8(+) T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes[J]. Cell, 2023, 186(6): 1127-1143.
24
Kotsakis A, Koinis F, Katsarou A, et al. Prognostic value of circulating regulatory T cell subsets in untreated non-small cell lung cancer patients[J]. Sci Rep, 2016, 6: 39247.
25
Reticker-Flynn NE, Zhang W, Belk JA, et al. Lymph node colonization induces tumor-immune tolerance to promote distant metastasis[J]. Cell, 2022, 185(11): 1924-42.e23.
26
Mickel RA, Kessler DJ, Taylor JM, et al. Natural killer cell cytotoxicity in the peripheral blood, cervical lymph nodes, and tumor of head and neck cancer patients[J]. Cancer Res, 1988, 48(17): 5017-5022.
27
Teramoto K, Igarashi T, Kataoka Y, et al. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer[J]. Lung Cancer, 2019, 137: 56-63.
28
Zhai WY, Zhao ZR, Chen S, et al. Response of primary tumor and lymph node in non-small cell lung cancer after neoadjuvant immunotherapy: a pooled analysis[J]. J Immunother Cancer, 2022, 10(9): e005160.
29
孟芸畅,许可,宋勇. 新辅助免疫治疗在可切除非小细胞肺癌中的研究进展[J/OL]. 中华肺部疾病杂志(电子版), 2023, 16(5): 734-738.
30
Yang G, Cai S, Hu M, et al. Functional status and spatial architecture of tumor-infiltrating CD8+ T cells are associated with lymph node metastases in non-small cell lung cancer[J]. J Transl Med, 2023, 21(1): 320.
31
Du C, Chen Y, Zhou Y, et al. Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC[J]. BMC cancer, 2023, 23(1): 1260.
32
Barua S, Fang P, Sharma A, et al. Spatial interaction of tumor cells and regulatory T cells correlates with survival in non-small cell lung cancer[J]. Lung Cancer, 2018, 117: 73-79.
33
邹琴,龙玲,叶容,等. PD-1抑制剂免疫治疗NSCLC所致反应性毛细血管增生症的研究进展[J/OL]. 中华肺部疾病杂志(电子版), 2023, 16(2): 278-280.
34
Ishiguro F, Matsuo K, Fukui T, et al. Effect of selective lymph node dissection based on patterns of lobe-specific lymph node metastases on patient outcome in patients with resectable non-small cell lung cancer: a large-scale retrospective cohort study applying a propensity score[J]. J Thorac Cardiovasc Surg, 2010, 139(4): 1001-1006.
[1] 李雨秋, 莫红楠. 乳腺癌肿瘤微环境特征及免疫治疗新进展[J/OL]. 中华乳腺病杂志(电子版), 2025, 19(06): 331-338.
[2] 孙圣梅, 习一清, 安宁. 人表皮生长因子受体2阳性型乳腺癌新辅助治疗响应的基因预测模型[J/OL]. 中华普通外科学文献(电子版), 2025, 19(05): 332-339.
[3] 钱龙, 蔡大明, 王行舟, 艾世超, 胡琼源, 孙锋, 宋鹏, 王峰, 王萌, 陆晓峰, 朱欢欢, 沈晓菲, 管文贤. 局部不可切除胃癌转化治疗(联合免疫治疗)后淋巴结转移的相关危险因素分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(06): 624-627.
[4] 王思竣, 王琼, 李珂雨, 袁新普, 张硕珉, 马睿, 谢天宇, 张朝军. 胃上部癌新辅助化疗联合免疫治疗后实施近端胃切除术的临床疗效分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(06): 637-641.
[5] 高峰, 郝少龙, 孙浩, 韩威. 三级淋巴结构在胰腺癌中的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(05): 570-573.
[6] 廖志成, 朱黎, 曾志宇. 广东省医学会泌尿外科疑难病例多学科会诊(第27期)——晚期肾癌[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(05): 669-676.
[7] 李才坤, 张又红, 肖斌彬, 温盼, 刘醒, 刘志栋, 周剑辉, 温春玲, 叶劲, 严恒琛. 三维斑点追踪在肺癌患者免疫治疗后左心房功能损害评价的应用[J/OL]. 中华肺部疾病杂志(电子版), 2025, 18(05): 821-823.
[8] 骆鑫源, 王元昕, 周远畅, 陈可蕙, 李泽歆, 张基旺, 张磊升, 郑朝晖. 纳米材料在增强自然杀伤细胞靶向治疗中的应用研究进展[J/OL]. 中华细胞与干细胞杂志(电子版), 2025, 15(05): 312-320.
[9] 张宇涵, 吴添庆, 高汶卿, 郑梽楷, 贺珉睿, 周仲国. 不可切除性肝内胆管癌不同治疗方式疗效和安全性的Meta分析[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(06): 939-947.
[10] 许侨东, 马志延, 冯庚壬, 钟海彬, 刘坚锐, 古松钢. 肝肺多发性原发性癌转化治疗后行腹腔镜肝右前叶切除术一例(附视频)[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(06): 973-976.
[11] 胡铭语, 李敬东, 肖雨竹, 黄杰. 初始不可切除肝癌患者转化治疗序贯手术的临床疗效分析[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(05): 754-760.
[12] 赵南, 张明凯, Bhargava Divija, 赵世光, 张大明. 结直肠癌脑转移的临床特征与治疗策略进展[J/OL]. 中华结直肠疾病电子杂志, 2025, 14(05): 427-435.
[13] 中国医师协会结直肠肿瘤专业委员会免疫学组. 结直肠癌免疫治疗专家共识(2025版)[J/OL]. 中华结直肠疾病电子杂志, 2025, 14(04): 289-298.
[14] 王春茂, 韩鸣, 王子彤. 局限期小细胞肺癌新辅助治疗后完全病理学缓解五例[J/OL]. 中华临床医师杂志(电子版), 2025, 19(07): 550-554.
[15] 侯雨函, 姜福金, 王苏贵. 膀胱癌免疫治疗的研究进展[J/OL]. 中华临床医师杂志(电子版), 2025, 19(06): 471-475.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?